A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?

Title:A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?

Volume: 12 Issue: 1

Author(s): Wala Ben Kridis, Nabil Toumi, Hadil Chaari, Afef Khanfir, Kamel Ayadi, Hassib Keskes, Tahia Boudawara, Jamel Daoud and Mounir Frikha

Affiliation:

Keywords: Chemotherapy, ewing sarcoma, malignant bone tumors, prognostic factor, therapeutic strategies, treatment.

Abstract: Background: The Ewing sarcoma (ES) represents 10 to 15% malignant bone tumors and 40 to 45% pediatric malignant bone tumors. The aim of this review is to clarify the therapeutic results and prognostic factors of this entity.

Methods: A systematic review of the literature was performed. Studies focused on the management of ES were considered for inclusion.

Result: ES represents a model of multidisciplinary approach. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between the pediatric and medical oncologists. The overall 5- year survival of Ewing localized tumors was 70% versus 30% in metastatic ES.

Conclusion: The treatment of ES includes neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The role of high-dose chemotherapy is still debated.

Cite this article as:

Kridis Ben Wala, Toumi Nabil, Chaari Hadil, Khanfir Afef, Ayadi Kamel, Keskes Hassib, Boudawara Tahia, Daoud Jamel and Frikha Mounir, A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?, Reviews on Recent Clinical Trials 2017; 12 (1) . https://dx.doi.org/10.2174/1574887112666170120100147

DOI https://dx.doi.org/10.2174/1574887112666170120100147	Print ISSN 1574-8871
Publisher Name Bentham Science Publisher	Online ISSN 1876-1038